Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
Over the past two decades, 11 biologic agents have been approved for use in most countries for the treatment of moderate-to-severe inflammatory bowel disease (IBD). Antitumor necrosis factor α (anti-TNF) agents are commonly used as the first biologic in clinical practice, and nearly all pivotal stud...
Main Author: | Brian Bressler |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-04-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/17562848231159452 |
Similar Items
-
Biologic therapies for chronic inflammatory bowel disease
by: M. P. Martínez-Montiel, et al. -
Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases
by: Gian Paolo Caviglia, et al.
Published: (2021-12-01) -
Safety of Biologic Therapy in Older Adults with Inflammatory Bowel Diseases
by: Tae-Geun Gweon
Published: (2023-05-01) -
Use of Biologics in Inflammatory Bowel Disease: Combination and Sequential Therapy
by: Putra Nur Hidayat, et al.
Published: (2022-09-01) -
Risk of Infections of Biological Therapies with Accent on Inflammatory Bowel Disease
by: Radu M Nanau, et al.
Published: (2014-10-01)